Alphatec (NASDAQ:ATEC) Posts Quarterly Earnings Results, Misses Estimates By $0.21 EPS

05 May 2026, 20:06 by Doug Wharley · The Cerbat Gem

Alphatec (NASDAQ:ATEC – Get Free Report) announced its quarterly earnings data on Tuesday. The medical technology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.21), Zacks reports. The firm had revenue of $192.11 million during the quarter, compared to analyst estimates of $197.51 million. During the same quarter last year, the firm earned ($0.35) EPS. The firm’s quarterly revenue was up 13.6% on a year-over-year basis.

Here are the key takeaways from Alphatec’s conference call:

Strong surgical momentum: Q1 revenue was $192M with surgical revenue of $178M (+17% YoY), driven by cases up 21% and new surgeons up 23%, which management says demonstrates a durable, compounding adoption model.
Improving profitability and balance sheet: Gross margin expanded to 71.6% and adjusted EBITDA was $21M (11% of revenue, +97% YoY) while a new term loan and revolver extend maturities to 2031 and are expected to cut interest expense materially.
Near-term EOS execution shortfall and guidance impact: EOS revenue fell to $14M in Q1 (down $3M YoY) due to fewer system deliveries and installation timing issues, prompting a reduced FY EOS outlook (~$77M) though the company is adding sales, marketing, and support resources.
EOS Insight remains a strategic long-term asset: Management highlights EOSedge installed base growth (U.S. +39% YoY), EOS Insight accounts more than doubled, meaningful implant pull-through post-go‑live, and a claimed ~30% revenue lift per surgeon after Insight adoption, supporting the platform/moat thesis.

Alphatec Stock Down 1.0%

NASDAQ ATEC traded down $0.10 during midday trading on Tuesday, hitting $10.23. 7,527,616 shares of the company traded hands, compared to its average volume of 3,005,302. The company has a debt-to-equity ratio of 40.35, a current ratio of 2.06 and a quick ratio of 1.28. The company has a market cap of $1.57 billion, a PE ratio of -10.77 and a beta of 0.96. The company’s 50-day simple moving average is $11.73 and its 200-day simple moving average is $15.95. Alphatec has a 52 week low of $9.11 and a 52 week high of $23.29.

Insider Buying and Selling

In other news, EVP Craig E. Hunsaker sold 82,765 shares of the stock in a transaction on Monday, March 9th. The stock was sold at an average price of $12.45, for a total transaction of $1,030,424.25. Following the completion of the sale, the executive vice president owned 1,726,209 shares in the company, valued at approximately $21,491,302.05. This represents a 4.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP David Sponsel sold 163,452 shares of the stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $12.52, for a total value of $2,046,419.04. Following the sale, the executive vice president owned 504,932 shares of the company’s stock, valued at approximately $6,321,748.64. This represents a 24.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 689,614 shares of company stock worth $8,634,850 over the last quarter. Insiders own 22.80% of the company’s stock.

Institutional Trading of Alphatec

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Voloridge Investment Management LLC purchased a new stake in shares of Alphatec during the 4th quarter valued at $321,000. Susquehanna Portfolio Strategies LLC purchased a new position in Alphatec in the 4th quarter worth $681,000. Numerai GP LLC purchased a new position in Alphatec in the 4th quarter worth $757,000. Occudo Quantitative Strategies LP raised its stake in Alphatec by 235.4% in the 4th quarter. Occudo Quantitative Strategies LP now owns 269,798 shares of the medical technology company’s stock worth $5,677,000 after acquiring an additional 189,348 shares during the last quarter. Finally, Millennium Management LLC grew its position in Alphatec by 292.2% during the 4th quarter. Millennium Management LLC now owns 2,225,927 shares of the medical technology company’s stock worth $46,834,000 after purchasing an additional 1,658,349 shares during the period. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ATEC shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alphatec in a research report on Friday, March 27th. Stifel Nicolaus decreased their price objective on Alphatec from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, March 9th. Lake Street Capital reaffirmed a “buy” rating on shares of Alphatec in a research note on Wednesday, February 25th. Piper Sandler reaffirmed an “overweight” rating on shares of Alphatec in a research note on Wednesday, February 25th. Finally, TD Cowen reissued a “buy” rating on shares of Alphatec in a research note on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.82.

Read Our Latest Research Report on Alphatec

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.